274 related articles for article (PubMed ID: 16731632)
1. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.
van der Sloot AM; Tur V; Szegezdi E; Mullally MM; Cool RH; Samali A; Serrano L; Quax WJ
Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8634-9. PubMed ID: 16731632
[TBL] [Abstract][Full Text] [Related]
2. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3.
Abdollahi T; Robertson NM; Abdollahi A; Litwack G
Cancer Res; 2003 Aug; 63(15):4521-6. PubMed ID: 12907626
[TBL] [Abstract][Full Text] [Related]
3. [Correlation between sensitivity to TRAIL and expression level of DR5 on surface of tumor cells].
Ma YF; Zhang J; Zhao YP; Yang DL; Chen YH
Zhonghua Zhong Liu Za Zhi; 2004 Sep; 26(9):528-30. PubMed ID: 15555281
[TBL] [Abstract][Full Text] [Related]
4. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor.
Wu GS; Burns TF; Zhan Y; Alnemri ES; El-Deiry WS
Cancer Res; 1999 Jun; 59(12):2770-5. PubMed ID: 10383128
[TBL] [Abstract][Full Text] [Related]
5. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway.
He Q; Lee DI; Rong R; Yu M; Luo X; Klein M; El-Deiry WS; Huang Y; Hussain A; Sheikh MS
Oncogene; 2002 Apr; 21(17):2623-33. PubMed ID: 11965535
[TBL] [Abstract][Full Text] [Related]
6. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
Spierings DC; de Vries EG; Timens W; Groen HJ; Boezen HM; de Jong S
Clin Cancer Res; 2003 Aug; 9(9):3397-405. PubMed ID: 12960128
[TBL] [Abstract][Full Text] [Related]
7. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas.
Koornstra JJ; Kleibeuker JH; van Geelen CM; Rijcken FE; Hollema H; de Vries EG; de Jong S
J Pathol; 2003 Jul; 200(3):327-35. PubMed ID: 12845629
[TBL] [Abstract][Full Text] [Related]
8. Rheumatoid arthritis synovial fluid macrophages express decreased tumor necrosis factor-related apoptosis-inducing ligand R2 and increased decoy receptor tumor necrosis factor-related apoptosis-inducing ligand R3.
Perlman H; Nguyen N; Liu H; Eslick J; Esser S; Walsh K; Moore TL; Pope RM
Arthritis Rheum; 2003 Nov; 48(11):3096-101. PubMed ID: 14613271
[TBL] [Abstract][Full Text] [Related]
9. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation.
Mongkolsapaya J; Grimes JM; Chen N; Xu XN; Stuart DI; Jones EY; Screaton GR
Nat Struct Biol; 1999 Nov; 6(11):1048-53. PubMed ID: 10542098
[TBL] [Abstract][Full Text] [Related]
10. Thapsigargin potentiates TRAIL-induced apoptosis in giant cell tumor of bone.
Huang L; Xu J; Li K; Zheng MH; Kumta SM
Bone; 2004 Jun; 34(6):971-81. PubMed ID: 15193543
[TBL] [Abstract][Full Text] [Related]
11. TRAIL/Apo2L ligands induce apoptosis in malignant rhabdoid tumor cell lines.
Yoshida S; Narita T; Koshida S; Ohta S; Takeuchi Y
Pediatr Res; 2003 Nov; 54(5):709-17. PubMed ID: 12904602
[TBL] [Abstract][Full Text] [Related]
12. Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia.
Johnston JB; Kabore AF; Strutinsky J; Hu X; Paul JT; Kropp DM; Kuschak B; Begleiter A; Gibson SB
Oncogene; 2003 Nov; 22(51):8356-69. PubMed ID: 14614459
[TBL] [Abstract][Full Text] [Related]
13. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene.
Guan B; Yue P; Clayman GL; Sun SY
J Cell Physiol; 2001 Jul; 188(1):98-105. PubMed ID: 11382926
[TBL] [Abstract][Full Text] [Related]
14. Additive effect of TRAIL and p53 gene transfer on apoptosis of human lung cancer cell lines.
Jang SH; Seol JY; Kim CH; Yoo CG; Kim YW; Han SK; Shim YS; Lee CT
Int J Mol Med; 2004 Jan; 13(1):181-6. PubMed ID: 14654992
[TBL] [Abstract][Full Text] [Related]
15. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.
Ichikawa K; Liu W; Zhao L; Wang Z; Liu D; Ohtsuka T; Zhang H; Mountz JD; Koopman WJ; Kimberly RP; Zhou T
Nat Med; 2001 Aug; 7(8):954-60. PubMed ID: 11479629
[TBL] [Abstract][Full Text] [Related]
16. TRAIL (Apo-2L) and TRAIL receptors in human placentas: implications for immune privilege.
Phillips TA; Ni J; Pan G; Ruben SM; Wei YF; Pace JL; Hunt JS
J Immunol; 1999 May; 162(10):6053-9. PubMed ID: 10229846
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
Fan QL; Zou WY; Song LH; Wei W
Cancer Chemother Pharmacol; 2005 Feb; 55(2):189-96. PubMed ID: 15290100
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells.
Miyashita T; Kawakami A; Nakashima T; Yamasaki S; Tamai M; Tanaka F; Kamachi M; Ida H; Migita K; Origuchi T; Nakao K; Eguchi K
Clin Exp Immunol; 2004 Aug; 137(2):430-6. PubMed ID: 15270863
[TBL] [Abstract][Full Text] [Related]
19. Specificity of molecular recognition learned from the crystal structures of TRAIL and the TRAIL:sDR5 complex.
Cha SS; Song YL; Oh BH
Vitam Horm; 2004; 67():1-17. PubMed ID: 15110168
[TBL] [Abstract][Full Text] [Related]
20. Apo2L/TRAIL and its death and decoy receptors.
LeBlanc HN; Ashkenazi A
Cell Death Differ; 2003 Jan; 10(1):66-75. PubMed ID: 12655296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
